Lupin Earns Top CDP A Rating for Efforts in Combating Climate Change and Conserving Water
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional performance in Climate Change and Water Security. This recognition is a testament to Lupin’s commitment to sustainability and transparency, placing the company among the world’s leading organizations that prioritize environmental stewardship.
Lupin’s double ‘A’ rating in Climate and Water demonstrates its proactive approach to mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. This achievement represents a significant improvement from the company’s previous ratings, with a substantial enhancement from ‘A-‘ in 2024 and ‘B’ in 2023 for climate, and ‘C’ for water. This progress reflects Lupin’s dedication to continuous improvement and its efforts to establish new sustainability standards.
The company’s Executive Director, Ramesh Swaminathan, attributed this achievement to Lupin’s innovative approaches, collaborative efforts, and transparency. He emphasized that the CDP’s framework has helped shape and accelerate the company’s climate initiatives, driving ongoing progress. Lupin’s commitment to sustainability is also reflected in its S&P Global ESG score of 91 in 2025, which is a best-in-class global achievement. This score positions Lupin among a select group of companies worldwide that have surpassed the 90-point threshold, demonstrating its exceptional performance in environmental, social, and governance (ESG) aspects.
Lupin’s achievement is a significant milestone in the pharmaceutical industry, highlighting the company’s dedication to reducing its environmental impact while generating lasting value for its communities and the planet. By prioritizing sustainability and transparency, Lupin is setting a high standard for the industry and demonstrating its commitment to creating a better future for all stakeholders. Overall, Lupin’s double ‘A’ rating from CDP and its exceptional ESG score are a testament to the company’s leadership in sustainability and its efforts to make a positive impact on the environment.
US FDA Concludes Inspection at Zydus’ Ankleshwar Facility with Three Noted Observations.
The US Food and Drug Administration (USFDA) has completed an inspection at Zydus Cadila’s manufacturing facility in Ankleshwar, Gujarat, with three observations. The inspection was conducted from February 13 to February 17, 2023. Although the company has not provided detailed information about the observations, it has stated that they are not related to data integrity or repeat observations from previous inspections.
The Ankleshwar plant is a key manufacturing facility for Zydus Cadila, producing a range of pharmaceutical products, including injectables, oral solids, and topical formulations. The USFDA inspection is a critical step in ensuring compliance with regulatory requirements for products exported to the US market. The observations made by the USFDA are considered minor, and the company is expected to respond to them within a specified timeframe.
Zydus Cadila has a history of USFDA inspections at its various manufacturing facilities. In 2020, the company’s Moraiya facility received a warning letter from the USFDA, citing several observations related to quality control and manufacturing practices. However, the company has since taken corrective actions and has been working to improve its compliance with regulatory requirements.
The outcome of the recent inspection at the Ankleshwar plant is seen as a positive development for Zydus Cadila, as it indicates that the company is on the right track in terms of compliance with USFDA regulations. The company’s management has stated that it is committed to maintaining high standards of quality and compliance at all its manufacturing facilities.
The inspection outcome is also significant for the Indian pharmaceutical industry as a whole, as it demonstrates the country’s ability to produce high-quality pharmaceutical products that meet international regulatory standards. India is a major player in the global pharmaceutical industry, with many companies exporting products to the US and other countries.
In conclusion, the USFDA’s inspection at Zydus Cadila’s Ankleshwar plant with three observations is a positive development for the company and the Indian pharmaceutical industry. While the observations are minor, the company will need to respond to them promptly to ensure compliance with regulatory requirements. The inspection outcome highlights the importance of maintaining high standards of quality and compliance in the pharmaceutical industry, and Zydus Cadila’s commitment to these principles is expected to support its growth and success in the global market.
A recall has been issued for a batch of MS medication after it was found that the capsules were dissolving at a slower rate than expected.
A batch of a multiple sclerosis (MS) medication has been recalled due to a manufacturing issue that affects the dissolution of the capsules. The medication, called Copaxone, is a glatiramer acetate injection used to treat relapsing forms of MS. The recall was initiated by the manufacturer, Teva Pharmaceuticals, after it was discovered that some capsules may not be dissolving at the expected rate.
The issue was identified during routine testing, which revealed that some capsules were not meeting the required dissolution specifications. As a result, Teva Pharmaceuticals has recalled the affected batch, which was distributed in the UK and other countries. The company has stated that the recall is a precautionary measure to ensure the quality and efficacy of the medication.
The slow dissolution of the capsules may affect the release of the active ingredient, glatiramer acetate, which could potentially impact the medication’s effectiveness in managing MS symptoms. However, Teva Pharmaceuticals has emphasized that there is no evidence to suggest that the affected batch poses a safety risk to patients.
Patients who are currently taking Copaxone are advised to check their medication packaging to see if it is part of the recalled batch. The affected batch numbers and expiry dates can be found on the Medicines and Healthcare products Regulatory Agency (MHRA) website. If a patient has a recalled batch, they should contact their pharmacist or healthcare provider for advice on what to do next.
Teva Pharmaceuticals has assured patients that alternative supplies of Copaxone are available, and that they are working to rectify the issue as quickly as possible. The company has also stated that it is cooperating fully with regulatory authorities to resolve the issue.
The recall highlights the importance of quality control measures in the pharmaceutical industry. Regular testing and inspection of medications are crucial to ensuring that they meet the required standards of quality, safety, and efficacy. The MHRA has stated that it is monitoring the situation closely and will take further action if necessary to protect public health.
In the meantime, patients with MS are advised to continue taking their medication as prescribed, unless advised otherwise by their healthcare provider. If patients have any concerns or questions about the recall, they should contact their pharmacist or healthcare provider for guidance and support.
Lupin Achieves Top ESG Score from CDP for Efforts in Combating Climate Change and Ensuring Water Security – Reported by Chennai Patrika.
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition solidifies Lupin’s position as a global leader in championing sustainability and transparency. The company’s double ‘A’ rating in Climate and Water is a testament to its commitment to mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations.
This achievement represents a substantial improvement from Lupin’s previous ratings, with the company moving from ‘A-‘ in 2024 to ‘A’ in 2025, and from ‘B’ in 2023 to ‘A’ in 2025 for climate and water, respectively. This significant year-over-year progress demonstrates Lupin’s dedication to sustainability and its proactive initiatives aimed at reducing its environmental impact.
Ramesh Swaminathan, Executive Director, Global CFO and Head of API Plus SBU at Lupin, expressed pride in the company’s achievement, stating that Lupin has advanced its efforts to reduce environmental impact through innovation, collaboration, and transparency. He also acknowledged the role of CDP’s strict framework in shaping and accelerating the company’s climate initiatives, fostering ongoing progress.
In addition to the CDP rating, Lupin has also achieved an S&P Global ESG score of 91 in 2025, a best-in-class global achievement that positions the company among a distinguished group of companies worldwide that have surpassed the 90-point threshold. This recognition demonstrates Lupin’s commitment to establishing new sustainability standards and generating lasting value for its communities and the planet. Overall, Lupin’s achievements in sustainability and environmental responsibility underscore its position as a responsible and forward-thinking global pharmaceutical leader.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.